Recent advances in anti-survivin treatments for cancer

R. K. Kanwar, Chun-Hei Cheung, Jang-Yang Chang, J. R. Kanwar

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Apoptosis occurs via extrinsic or intrinsic signalling each triggered and regulated by many different molecular pathways. In recent years, the selective induction of apoptosis through survivin in tumour cells has been increasingly recognized as a promising approach for cancer therapy. Survivin has multiple functions including cytoprotection, inhibition of cell death, and cell-cycle regulation, especially at the mitotic process stage, all of which favour cancer survival. Many studies on clinical specimens have shown that survivin over expression is invariably up regulated in human cancers, associated with resistance to chemotherapy or radiation therapy, and linked to poor prognosis, suggesting that cancer cells survive with survivin. On the basis of these findings, survivin has been proposed as an attractive target for new anticancer interventions. Survivin inhibitors recently entered clinical trials. Recent studies suggest a possible role for survivin in regulating the function of normal adult cells. However, the expression and function of survivin in normal tissues are still not well characterized and understood. Still better understandings of survivin's role in tumour versus normal cells are needed for designing the strategies to selectively disrupt survivin in cancers. In the present review, we summarise the importance of recent survivin-targeted cancer therapy for future clinical application.

Original languageEnglish
Pages (from-to)1509-1515
Number of pages7
JournalCurrent Medicinal Chemistry
Volume17
Issue number15
DOIs
Publication statusPublished - 2010 Jun 18

Fingerprint

Cells
Tumors
Apoptosis
Neoplasms
Chemotherapy
Radiotherapy
Cell death
Therapeutics
Tissue
Cytoprotection
Cell Cycle
Cell Death
Clinical Trials
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

@article{0ab55485ee7342199f93e60c20051a59,
title = "Recent advances in anti-survivin treatments for cancer",
abstract = "Apoptosis occurs via extrinsic or intrinsic signalling each triggered and regulated by many different molecular pathways. In recent years, the selective induction of apoptosis through survivin in tumour cells has been increasingly recognized as a promising approach for cancer therapy. Survivin has multiple functions including cytoprotection, inhibition of cell death, and cell-cycle regulation, especially at the mitotic process stage, all of which favour cancer survival. Many studies on clinical specimens have shown that survivin over expression is invariably up regulated in human cancers, associated with resistance to chemotherapy or radiation therapy, and linked to poor prognosis, suggesting that cancer cells survive with survivin. On the basis of these findings, survivin has been proposed as an attractive target for new anticancer interventions. Survivin inhibitors recently entered clinical trials. Recent studies suggest a possible role for survivin in regulating the function of normal adult cells. However, the expression and function of survivin in normal tissues are still not well characterized and understood. Still better understandings of survivin's role in tumour versus normal cells are needed for designing the strategies to selectively disrupt survivin in cancers. In the present review, we summarise the importance of recent survivin-targeted cancer therapy for future clinical application.",
author = "Kanwar, {R. K.} and Chun-Hei Cheung and Jang-Yang Chang and Kanwar, {J. R.}",
year = "2010",
month = "6",
day = "18",
doi = "10.2174/092986710790979935",
language = "English",
volume = "17",
pages = "1509--1515",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "15",

}

Recent advances in anti-survivin treatments for cancer. / Kanwar, R. K.; Cheung, Chun-Hei; Chang, Jang-Yang; Kanwar, J. R.

In: Current Medicinal Chemistry, Vol. 17, No. 15, 18.06.2010, p. 1509-1515.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recent advances in anti-survivin treatments for cancer

AU - Kanwar, R. K.

AU - Cheung, Chun-Hei

AU - Chang, Jang-Yang

AU - Kanwar, J. R.

PY - 2010/6/18

Y1 - 2010/6/18

N2 - Apoptosis occurs via extrinsic or intrinsic signalling each triggered and regulated by many different molecular pathways. In recent years, the selective induction of apoptosis through survivin in tumour cells has been increasingly recognized as a promising approach for cancer therapy. Survivin has multiple functions including cytoprotection, inhibition of cell death, and cell-cycle regulation, especially at the mitotic process stage, all of which favour cancer survival. Many studies on clinical specimens have shown that survivin over expression is invariably up regulated in human cancers, associated with resistance to chemotherapy or radiation therapy, and linked to poor prognosis, suggesting that cancer cells survive with survivin. On the basis of these findings, survivin has been proposed as an attractive target for new anticancer interventions. Survivin inhibitors recently entered clinical trials. Recent studies suggest a possible role for survivin in regulating the function of normal adult cells. However, the expression and function of survivin in normal tissues are still not well characterized and understood. Still better understandings of survivin's role in tumour versus normal cells are needed for designing the strategies to selectively disrupt survivin in cancers. In the present review, we summarise the importance of recent survivin-targeted cancer therapy for future clinical application.

AB - Apoptosis occurs via extrinsic or intrinsic signalling each triggered and regulated by many different molecular pathways. In recent years, the selective induction of apoptosis through survivin in tumour cells has been increasingly recognized as a promising approach for cancer therapy. Survivin has multiple functions including cytoprotection, inhibition of cell death, and cell-cycle regulation, especially at the mitotic process stage, all of which favour cancer survival. Many studies on clinical specimens have shown that survivin over expression is invariably up regulated in human cancers, associated with resistance to chemotherapy or radiation therapy, and linked to poor prognosis, suggesting that cancer cells survive with survivin. On the basis of these findings, survivin has been proposed as an attractive target for new anticancer interventions. Survivin inhibitors recently entered clinical trials. Recent studies suggest a possible role for survivin in regulating the function of normal adult cells. However, the expression and function of survivin in normal tissues are still not well characterized and understood. Still better understandings of survivin's role in tumour versus normal cells are needed for designing the strategies to selectively disrupt survivin in cancers. In the present review, we summarise the importance of recent survivin-targeted cancer therapy for future clinical application.

UR - http://www.scopus.com/inward/record.url?scp=77953509436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953509436&partnerID=8YFLogxK

U2 - 10.2174/092986710790979935

DO - 10.2174/092986710790979935

M3 - Article

VL - 17

SP - 1509

EP - 1515

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 15

ER -